Using AI To Personalize Healthcare–Without Losing Patient Trust
In this week’s edition of InnovationRx, the focus is on the potential and challenges of utilizing AI to personalize healthcare and expedite clinical trials, the future of genetic medicine, another significant acquisition by Lilly, and more.
At the Adobe Summit in Las Vegas, discussions centered on AI and its application in personalizing healthcare delivery. Blue Shield of California’s CMO, Jigar Shah, emphasized the uniqueness of each individual’s healthcare journey due to their biology. The adoption of technology in healthcare has been slower compared to other industries due to regulatory constraints, siloed systems, and legacy technologies. Tory Smithe from Adobe highlighted the importance of seeing regulations as a means to serve patients, as exemplified by Blue Shield’s proactive implementation of price transparency. Lesley Spellmeyer from Lilly discussed how AI allows healthcare companies to provide proactive information to patients and providers, enhancing the overall healthcare experience.
While AI offers numerous advantages, panelists emphasized the need to implement it in a way that maintains trust among patients and healthcare professionals. Amanda Todorovich from Cleveland Clinic stressed the importance of human oversight in content creation, ensuring that all published material undergoes medical review. The consensus among panelists was that maintaining a human touch, particularly through healthcare professionals, is crucial for building trust and delivering information effectively.
The article also highlights Formation Bio, a startup founded by Benjamine Liu and Linhao Zhang, aiming to utilize AI to enhance the efficiency of drug development and clinical trials. The company has attracted significant investment and is focused on reviving stalled drug candidates using AI technology.
Katherine High, a Breakthrough Prize winner, was recognized for her work in genetic medicine, specifically in developing Luxturna, the first FDA-approved gene replacement therapy. High expressed optimism about the future of genetic medicine, citing advancements in treatment administration.
Eli Lilly’s latest acquisition of Kelonia Therapeutics for $3.25 billion upfront, with a potential total value of $7 billion, highlights the pharmaceutical giant’s focus on genetic medicine. Kelonia is developing an innovative CAR-T treatment for multiple myeloma that operates within the patient’s body, distinguishing it from traditional CAR-T therapies.
The article also covers recent developments in the biotech industry, including the surge in stocks of companies developing psychedelic medicines following regulatory developments, and Kailera’s successful $625 million IPO. Additionally, Merck’s partnership with Google Cloud to implement AI across its business signifies the growing influence of AI in healthcare and pharmaceuticals.
For more insights and updates on the latest trends in healthcare and biotech, stay tuned to Forbes.
